KRAS and cancer: Furthermore, the sensitivity to trametinib was inversely correlated with RPS5 dependency in survival of KRAS-mutant with p53 wild type cells (n = 20, Pearson correlation = −0.5757, P < 0.01),  while no such trend was observed for the other types of cancer (n = 286; Fig. 4F), suggesting that p53 induction is associated with trametinib-induced cell death in RPS5-depleted cells.